Revenue has contracted to zero in recent quarters, while persistent R&D expenses continue to drive operating losses, as evidenced by the $3.4 million operating loss reported in 2026Q1.
| Sales/Revenue | 118.11K | 0 | 1.5M | 583.23K | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | -90.8% | -100% | 157.63% | - | - | - | - | - | - | - |
| Cost of Goods Sold | 1.92M | 0 | 9.36M | 7.05K | 16.4M | 271.68K | 229.61K | 170.25K | 8.32K | 7.93K |
| COGS % of Revenue | - | - | 623.16% | 1.21% | - | - | - | - | - | - |
| Gross Profit | -1.8M | 0 | -7.86M | 576.18K | -16.4M | -271.68K | -229.61K | -170.25K | -8.32K | -7.93K |
| Gross Margin % | -1523.59% | - | -523.16% | 98.79% | - | - | - | - | - | - |
| Gross Profit Growth % | - | 100% | -1464.33% | 103.51% | -5937.42% | -18.32% | -34.86% | -1947.31% | -4.84% | - |
| Operating Expenses | 10.78M | 13.23M | 6.46M | 16.05M | 96.99M | 37.17M | 52.81M | 29.37M | 16.49M | 15.85M |
| OpEx % of Revenue | - | - | 429.84% | 2751.59% | - | - | - | - | - | - |
| Selling, General & Admin | 6.53M | 6.48M | 6.46M | 8.42M | 20.97M | 13.55M | 14.93M | 8.42M | 2.29M | 2.46M |
| SG&A % of Revenue | - | - | 429.84% | 1443.79% | - | - | - | - | - | - |
| Research & Development | 6.17M | 7.04M | 9.36M | 7.63M | 92.42M | 23.9M | 37.88M | 20.95M | 14.19M | 13.39M |
| R&D % of Revenue | - | - | 623.16% | 1307.8% | - | - | - | - | - | - |
| Other Operating Expenses | -1.01M | -285.76K | -9.36M | 0 | -16.4M | -271.68K | 0 | 0 | 0 | 0 |
| Operating Income | -12.58M | -13.23M | -14.32M | -15.47M | -113.39M | -37.45M | -52.81M | -29.54M | -16.49M | -15.85M |
| Operating Margin % | -10649.87% | - | -953% | -2652.8% | - | - | - | - | - | - |
| Operating Income Growth % | - | 7.58% | 7.45% | 86.36% | -202.81% | 29.09% | -78.75% | -79.17% | -4.02% | - |
| EBITDA | -12.56M | -13.21M | -14.3M | -15.46M | -113.39M | -37.17M | -52.58M | -29.37M | -16.48M | -15.84M |
| EBITDA Margin % | -10631.48% | - | -951.52% | -2651.59% | - | - | - | - | - | - |
| EBITDA Growth % | 17.57% | 7.59% | 7.55% | 86.36% | -205.01% | 29.3% | -79.01% | -78.23% | -4.02% | - |
| D&A (Non-Cash Add-back) | 21.71K | 21.71K | 22.32K | 7.05K | 4.4K | 271.68K | 229.61K | 170.25K | 8.32K | 7.93K |
| EBIT | -12.58M | -13.23M | -14.32M | -14.29M | -37.37M | -37.13M | -53.48M | -28.06M | -15.53M | -15.19M |
| Net Interest Income | 582.14K | 652.09K | 1.29M | 1.22M | 0 | 1.65K | 0 | -156.35K | 0 | 0 |
| Interest Income | 582.14K | 652.09K | 1.29M | 1.22M | 448.67K | 1.65K | 222.65K | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 448.67K | 0 | 222.65K | 156.35K | 182 | 15 |
| Other Income/Expense | 623.84K | 634.27K | 1.36M | 1.19M | 730.2K | 319.05K | -667.6K | 1.48M | 961.13K | 662.13K |
| Pretax Income | -11.95M | -12.6M | -12.96M | -14.29M | -112.66M | -37.13M | -53.48M | -28.06M | -15.53M | -15.19M |
| Pretax Margin % | -10121.69% | - | -862.43% | -2449.59% | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -11.95M | -12.6M | -12.96M | -14.29M | -112.66M | -36.54M | -53.92M | -28.06M | -15.53M | -15.19M |
| Net Margin % | -10121.69% | - | -862.43% | -2449.59% | - | - | - | - | - | - |
| Net Income Growth % | 15.1% | 2.77% | 9.3% | 87.32% | -208.35% | 32.24% | -92.15% | -80.7% | -2.23% | - |
| Net Income (Continuing) | -11.95M | -12.6M | -12.96M | -14.29M | -112.66M | -37.13M | -53.48M | -28.06M | -15.53M | -15.19M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.56 | -1.93 | -2.35 | -3.95 | -1359.79 | -34.88 | -50.61 | -26.28 | -22.06 | -21.58 |
| EPS Growth % | 26.16% | 17.87% | 40.51% | 99.71% | -3798.48% | 31.08% | -92.58% | -19.13% | -2.22% | - |
| EPS (Basic) | - | -1.93 | -2.35 | -3.95 | -1359.79 | -34.88 | -50.61 | -26.28 | -22.06 | -21.58 |
| Diluted Shares Outstanding | 7.69M | 6.54M | 5.51M | 3.62M | 82.85K | 1.06M | 1.06M | 1M | 703.78K | 703.78K |
| Basic Shares Outstanding | 7.69M | 6.54M | 5.51M | 3.62M | 82.85K | 1.06M | 1.06M | 1M | 703.78K | 703.78K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Imminent liquidity and dilution
As indicated by the company's recent financial disclosures, revenue has effectively evaporated, falling to zero in the most recent quarter compared to historical peaks, signaling a complete transition away from legacy commercial activities toward a high-risk, pre-revenue clinical development model for its ATR inhibitor pipeline.
The total cessation of revenue suggests that the company has fully abandoned its previous commercial or licensing efforts to focus exclusively on the ATRN-119 program. Investors should interpret this as a binary shift where future top-line growth is entirely dependent on successful clinical trial readouts rather than existing product sales.
Based on the provided income statement data, R&D expenses remain the primary driver of the company's cash outflow, consistently consuming millions per quarter despite the lack of offsetting revenue, which highlights the heavy financial burden of maintaining clinical-stage oncology trials in a competitive landscape.
The persistence of R&D spending at levels exceeding $1 million per quarter, even as revenue has vanished, underscores the rigid cost structure inherent in biotech development. This expense discipline appears focused on survival rather than efficiency, as the company lacks the scale to optimize its clinical research organization expenditures.
Financial statements reveal that operating losses have persisted throughout the observed ten-quarter period, with the company failing to demonstrate any meaningful operating leverage as R&D and SG&A costs continue to outpace the negligible revenue generated by the firm's evolving and currently non-commercial business model.
The absence of positive operating margins suggests that the company is currently unable to scale its operations effectively. Without a commercial product to provide a base for overhead absorption, the operating loss remains a direct reflection of the company's ongoing clinical development intensity.
According to the latest quarterly figures, the company's cash position of $14.6 million against recurring quarterly operating losses suggests a precarious financial runway, raising significant concerns regarding the firm's ability to fund its clinical pipeline without resorting to highly dilutive equity financing in the near term.
The current burn rate relative to the reported cash balance warrants extreme caution, as it implies that the company may face a liquidity crisis before reaching critical clinical milestones. This financial constraint may force management into unfavorable capital raises, further eroding shareholder value and complicating the long-term investment thesis.
Quick answers to the most common questions about buying APRE stock.
For fiscal year 2025, Aprea Therapeutics, Inc. (APRE) reported total revenue of $0.0M.
Aprea Therapeutics, Inc. (APRE) reported a net loss of $12.6M for the fiscal year ending 2025.